CSL appoints Deborah Waterhouse as CEO & Managing Director
CSL Limited's board unanimously appointed Deborah Waterhouse as CEO and Managing Director effective 1 February 2027, concluding an extensive global search. Waterhouse has been CEO of ViiV Healthcare since 2017 — the GSK-majority HIV joint venture with £7.7 billion in FY25 sales — and previously led GSK's US vaccines and primary care businesses. Chair Brian McNamee cited her record of commercial momentum, pipeline renewal, and operational simplification. Gordon Naylor remains Interim CEO until the transition date, then returns to the Board as a non-executive director.
Key figures
- Start date
- 1 February 2027
- Base salary
- £1,500,000 per annum
- Viiv sales fy25
- £7.7 billion
- Gsk award buyout
- £7.71m in RSUs
- Additional lti award
- £1.65m in PSUs
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.